These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

794 related items for PubMed ID: 15756285

  • 1. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).
    Michallet AS, Nicolini F, Fürst S, Le QH, Dubois V, Hayette S, Bourgeot JP, Tremisi JP, Thomas X, Gebuhrer L, Michallet M.
    Bone Marrow Transplant; 2005 Mar; 35(6):601-8. PubMed ID: 15756285
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 4. Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation.
    Ferrá C, Rodríguez-Luaces M, Gallardo D, Encuentra M, Martín-Henao GA, Peris J, Ancín I, Sarrá J, Berlanga JJ, García J, Grañena A.
    Bone Marrow Transplant; 2001 Nov; 28(10):963-8. PubMed ID: 11753552
    [Abstract] [Full Text] [Related]

  • 5. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ, Hochberg EP, Alyea EP, Longtine J, Lee S, Galinsky I, Parekkedon B, Ritz J, Antin JH, Stone RM, Soiffer RJ.
    Clin Cancer Res; 2004 Aug 01; 10(15):5065-71. PubMed ID: 15297408
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
    Peggs KS, Mackinnon S, Williams CD, D'Sa S, Thuraisundaram D, Kyriakou C, Morris EC, Hale G, Waldmann H, Linch DC, Goldstone AH, Yong K.
    Biol Blood Marrow Transplant; 2003 Apr 01; 9(4):257-65. PubMed ID: 12720218
    [Abstract] [Full Text] [Related]

  • 10. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR, McAfee S, Sackstein R, Colby C, Saidman S, Weymouth D, Poliquin C, Vanderklish J, Sachs DH, Sykes M, Spitzer TR.
    Biol Blood Marrow Transplant; 2001 Apr 01; 7(11):604-12. PubMed ID: 11760148
    [Abstract] [Full Text] [Related]

  • 11. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions.
    Huff CA, Fuchs EJ, Smith BD, Blackford A, Garrett-Mayer E, Brodsky RA, Flinn IW, Ambinder RF, Borrello IM, Matsui WH, Vogelsang GB, Griffin CA, Luznik L, Jones RJ.
    Biol Blood Marrow Transplant; 2006 Apr 01; 12(4):414-21. PubMed ID: 16545725
    [Abstract] [Full Text] [Related]

  • 12. Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation.
    Chiorean EG, DeFor TE, Weisdorf DJ, Blazar BR, McGlave PB, Burns LJ, Brown C, Miller JS.
    Biol Blood Marrow Transplant; 2004 Mar 01; 10(3):171-7. PubMed ID: 14993882
    [Abstract] [Full Text] [Related]

  • 13. Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions.
    Sairafi D, Remberger M, Uhlin M, Ljungman P, Ringdén O, Mattsson J.
    Biol Blood Marrow Transplant; 2010 Dec 01; 16(12):1728-37. PubMed ID: 20542125
    [Abstract] [Full Text] [Related]

  • 14. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation.
    Savani BN, Montero A, Kurlander R, Childs R, Hensel N, Barrett AJ.
    Bone Marrow Transplant; 2005 Dec 01; 36(11):1009-15. PubMed ID: 16205732
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation.
    Glass B, Majolino I, Dreger P, Scimè R, Santoro A, Vasta S, Suttorp M, Haferlach T, Schmitz N.
    Bone Marrow Transplant; 1997 Oct 01; 20(7):533-41. PubMed ID: 9337054
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. High stem cell dose will not compensate for T cell depletion in allogeneic non-myeloablative stem cell transplantation.
    Passweg JR, Meyer-Monard S, Gregor M, Favre G, Heim D, Ebnoether M, Tichelli A, Gratwohl A.
    Bone Marrow Transplant; 2002 Sep 01; 30(5):267-71. PubMed ID: 12209347
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation.
    Lutz C, Massenkeil G, Nagy M, Neuburger S, Tamm I, Rosen O, Dörken B, Arnold R.
    Bone Marrow Transplant; 2008 May 01; 41(9):805-12. PubMed ID: 18195682
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.